1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics of the cohort according to actual treatment with endovascular therapy
PRove-IT Late-Window Cohort (n = 86)
Favorable mCTA Profile (n = 63) Favorable DEFUSE Profile (n = 58) Favorable DAWN Profile (n = 32)
EVT No EVT EVT No EVT EVT No EVT
No. 33 (52.4%) 30 (47.6%) 28 (48.3%) 30 (51.7%) 18 (56.3%) 14 (43.7%)
Age^{^a} 75 72 75 72 75 77
NIHSS score^{^a} 18 12 18 14 19 18
ASPECTS^{^a} 9 9 9 8 9 9
Onset/LSN to imaging (min)^{^a} 578 (9.6 hr) 580 (9.7 hr) 559 (9.3 hr) 571 (9.5 hr) 608 (10.1 hr) 593 (9.9 hr)
Occlusion site            
 Terminal ICA 12 (36.4%) 3 (10%) 10 (35.7%) 4 (13.3%) 7 (38.9%) 3 (21.4%)
 M1 14 (42.4%) 13 (43.3%) 10 (35.7%) 13 (43.3%) 6 (33.3%) 5 (35.7%)
 M2 6 (18.2%) 14 (46.7%) 7 (25%) 13 (43.3%) 4 (22.2%) 6 (42.9%)
 M3 or distal 1 (3%) 0 1 (3.6%) 0 1 (5.6%) 0
Note:—LSN indicates last seen normal.
↵a Denotes median.